| Literature DB >> 10028161 |
C A Osborne1, J P Lulich, J W Bartges, L K Ulrich, L A Koehler, K A Bird, L L Swanson, G W Austin, E L Prien, K U Steinam.
Abstract
Diagnostic and therapeutic drugs may enhance urolithiasis in one or a combination of ways, including: (1) alteration of urine pH in such fashion as to create an environment that increases the solubility of some lithogenic substances, (2) alteration of glomerular filtration rate, tubular reabsorption, and tubular secretion of drugs of endogenous substances so as to enhance promoters or impair inhibitors of urolithiasis, and (3) precipitation (e.g., drugs or their metabolites) to form a portion or all of a urolith.Entities:
Mesh：
Substances：
Year: 1999 PMID： 10028161 DOI： 10.1016/s0195-5616(99)50014-4
Source DB: PubMed Journal: Vet Clin North Am Small Anim Pract ISSN： 0195-5616 Impact factor: 2.093